This patient reminder card contains important safety information that you need to be aware of before and during treatment with Remicade.

Replagal HCP Guide

Replagal Patient Guide

This Algorithm provides high level steps for prescribing and dispensing of lenalidomide.

The FAQs (Frequently Asked Questions) provides answers to common questions that healthcare professionals may have about the medication.

This pack contains the all the additional Risk Minimisation Materials required to prescribe and dispense lenalidomide. It also contains important reporting forms, information for patients, prescribing tools, and the Pharmacy Registration Form. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood risk minimisation materials before prescribing or dispensing lenalidomide for any patient.

This brochure contains the information needed for prescribing and dispensing of lenalidomide, including information about the Pregnancy Prevention Programme. It is a requirement of the Pregnancy Prevention Programme that all healthcare professionals ensure that they have read and understood risk minimisation materials before prescribing or dispensing lenalidomide for any patient. Please also refer to the Summary of Product Characteristics (SmPC) for lenalidomide.

This brochure should be given to patients receiving treatment with lenalidomide, as it provides important information about the lenalidomide Pregnancy Prevention Programme, including what a patient needs to be aware of before, during and after taking lenalidomide and how to report side effects.

This Risk Awareness Form must be completed for each male patient prior to the initiation of their lenalidomide treatment. It is mandatory that male patients receive counselling and education to be made aware of the risks of lenalidomide. The aim of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of lenalidomide.

This card should be given to all patient as it reminds patients of the key educational information and risks of treatment with lenalidomide.

This Pharmacy Registration Form must be completed by the Chief Pharmacist or appointed deputy to be able to order and dispense lenalidomide. In order to ensure that the actions to minimise the risk of foetal exposure are carried out for all patients, dispensing of lenalidomide will only be allowed from pharmacies registered with BMS.

A newly completed Prescription Authorisation Form must accompany each lenalidomide prescription to confirm that the patient has been counselled about the teratogenic risk of lenalidomide and the required contraceptive methods, continues to use effective contraception and in the case of a woman of childbearing potential, is having a pregnancy test every 4 weeks before each prescription to ensure they are not pregnant. Completion of this information is mandatory for ALL patients.

This Risk Awareness Form must be completed for each woman of childbearing potential prior to the initiation of their lenalidomide treatment. It is mandatory that women of childbearing potential receive counselling and education to be made aware of the risks of lenalidomide. The aim of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of lenalidomide.

This Risk Awareness Form must be completed for each woman of non-childbearing potential prior to the initiation of their lenalidomide treatment. It is mandatory that women of non-childbearing potential receive counselling and education to be made aware of the risks of lenalidomide. The aim of the Risk Awareness Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of lenalidomide.

Important safety information for patients treated with: RIMMYRAH (ranibizumab) with visual impairment due to choroidal neovascularisation (CNV) secondary to pathological myopia

Important safety information for patients treated with: RIMMYRAH (ranibizumab) in wet (neovascular) age related macular degeneration (nAMD)

Important safety information for patients treated with: RIMMYRAH (ranibizumab) with proliferative diabetic retinopathy (PDR) and/or visual impairment due to diabetic macular oedema (DMO)

Important safety information for patients treated with: RIMMYRAH (ranibizumab) with visual impairment due to retinal vein occlusion (RVO)

Rinvoq Healthcare Professional Educational Guide

RINVOQ Patient Card - for medicines containing Upadacitinib

Rivaroxaban Prescriber Guide

Rivaroxaban-Patient Alert Card

Rivaroxaban Patient Alert Card

Rivaroxaban Prescriber Guide for HealthCare Professionals

Rivaroxaban patient alert card

Rivaroxaban prescriber guide

Rivaroxaban Prescriber Guide

Rivaroxaban-Patient Alert Card

Patient alert card for Rivaroxaban – noting patient’s anticoagulation treatment

Guide for Healthcare Professionals

Information on anticoagulation treatment with Rivaroxaban film-coated tablets

Important risk minimisation information for healthcare professionals

A patient alert card is provided with the product package to each patient who is prescribed Rivaroxaban. Prescribers are to explain the implications of anticoagulant treatment to patients and/or caregiver, in particular highlighting the need for: • Treatment compliance • Recognising signs or symptoms of bleeding • When to seek medical attention • The need to inform HCPs that they are taking rivaroxaban if they need to have any surgery or invasive procedure. The patient alert card will inform treating physicians and dentists about the patient‘s anticoagulation treatment and will contain emergency contact information.

This guide is to be used to support the appropriate use of Rivaroxaban. It includes the following information: • Dosing recommendations • Oral intake • Perioperative management • Contraindications • Overdose • How to manage bleeding complications • Coagulation testing

Rivaroxaban Patient Alert Card

Rivaroxaban Prescriber Guide

A patient alert card is provided with the product package to each patient who is prescribed Rivaroxaban. Prescribers are to explain the implications of anticoagulant treatment to patients and/or caregiver, in particular highlighting the need for: • Treatment compliance • Recognising signs or symptoms of bleeding • When to seek medical attention • The need to inform HCPs that they are taking rivaroxaban if they need to have any surgery or invasive procedure. The patient alert card will inform treating physicians and dentists about the patient‘s anticoagulation treatment and will contain emergency contact information.

A patient alert card is provided with the product package to each patient who is prescribed Rivaroxaban. Prescribers are to explain the implications of anticoagulant treatment to patients and/or caregiver, in particular highlighting the need for: • Treatment compliance • Recognising signs or symptoms of bleeding • When to seek medical attention • The need to inform HCPs that they are taking rivaroxaban if they need to have any surgery or invasive procedure. The patient alert card will inform treating physicians and dentists about the patient‘s anticoagulation treatment and will contain emergency contact information.

This guide is to be used to support the appropriate use of Rivaroxaban. It includes the following information: • Dosing recommendations • Oral intake • Perioperative management • Contraindications • Overdose • How to manage bleeding complications • Coagulation testing

Rivaroxaban Patient Alert Card

Rivaroxaban Prescriber Guide

Rivaroxaban Prescriber Guide

Rivaroxaban-Patient Alert Card

Rivaroxaban Patient Alert Card - 2.5mg, 10mg, 15mg, 20mg

RIVAROXABAN PRESCRIBER GUIDE

A healthcare professional card highlighting the route of administration for Rixathon Healthcare Professional

This guide is intended to review key facts and important safety information about rituximab in non-oncology diseases and to provide important patient counselling information to assist healthcare professionals in caring for patients receiving rituximab therapy.

Patient alert card

The information provided in this booklet should be discussed with patients by their healthcare professional during Rixathon(rituximab) treatment.

This material is provided by Roche Products Ltd as a license requirement for this medicine and forms part of the Risk Management Plan

This material is provided by Roche Products Ltd as a license requirement for this medicine and forms part of the Risk Management Plan

This material is provided by Roche Products Ltd as a license requirement for this medicine and forms part of the Risk Management Plan.

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

Healthcare professional educational material / checklist

Non-promotional educational materials of Immunological Assessments for the Healthcare Professional

Patient card

Patient educational material / checklist

Patient diary

Provides guidance on the route of administration (intravenous only), management, monitoring and safety considerations related to the risk management plan.

Provides help to patients to understand the risks associated with Ruxience and reminds them to seek immediate medical attention if they experience any of the listed signs and symptoms.

Provides information to patients on the risks, signs and symptoms of infection and the need to contact their doctor immediately if they experience them.

Information to provide guidance on Dosing and Administration of Rybrevant including Dosing Schedules and Modifications.